Cart
sales@molnova.com
MDL 29951
CAS No. 130798-51-5
MDL 29951( MDL 29951 | MDL-29951 | MDL29951 | MDL 29,951 )
Catalog No. M11231 CAS No. 130798-51-5
MDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 105 | In Stock |
|
| 5MG | 101 | In Stock |
|
| 10MG | 181 | In Stock |
|
| 25MG | 326 | In Stock |
|
| 50MG | 458 | In Stock |
|
| 100MG | 631 | In Stock |
|
| 200MG | 849 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMDL 29951
-
NoteResearch use only, not for human use.
-
Brief DescriptionMDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo.
-
DescriptionMDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo.
-
In Vitro——
-
In Vivo——
-
SynonymsMDL 29951 | MDL-29951 | MDL29951 | MDL 29,951
-
PathwayMembrane Transporter/Ion Channel
-
TargetNMDAR
-
RecptorNMDA receptor
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number130798-51-5
-
Formula Weight302.11
-
Molecular FormulaC12H9Cl2NO4
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESO=C(O)CCC1=C(C(O)=O)NC2=C1C(Cl)=CC(Cl)=C2
-
Chemical Name2-Carboxy-4,6-dichloro-1H-indole-3-propanoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Baron BM, et al. J Pharmacol Exp Ther. 1992 Sep;262(3):947-56.
molnova catalog
related products
-
D-AP5
D-AP5 is a NMDA receptor antagonist.
-
Felbamate
Felbamate (FBM) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
-
Transcrocetinate dis...
Transcrocetinate disodium extracted from saffron (Crocus sativus L.) is a high-affinity antagonist of NMDA receptor.
